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Background: Programmed cell death 1 receptor–ligand inter-
action is a major pathway often hijacked by tumors to suppress 
immune control. The aim of this retrospective study was to 
investigate the prevalence and prognostic roles of programmed 
cell death -ligand 1 (PD-L1) expression in small cell lung cancer 
(SCLC).
Methods: The expression of PD-L1 was evaluated by immunohisto-
chemical analysis in 102 specimens of SCLC. Tumors with staining 
in over 5% of tumor cells were scored as positive for PD-L1 expres-
sion. Survival analysis was performed using the Kaplan–Meier 
method.
Results: Expression of PD-L1 in tumor cells was observed in 
71.6% (73 of 102) of SCLCs, and was significantly correlated with 
a limited disease (LD) stage. SCLC patients with PD-L1-positive 
tumors showed significantly longer overall survival (OS) than 
those with PD-L1-negative (median OS, 16.3 versus 7.3 months; 
p < 0.001, respectively). Multivariate analyses demonstrated that 
a good performance status, LD stage, and expression of PD-L1 
were significantly predictive of better OS, independently of other 
factors. We found no relevance between PD-L1 expression and 
progression-free survival for first-line treatment in LD- and exten-
sive disease-SCLC patients.
Conclusions: In patients with SCLC, expression of PD-L1 is posi-
tively correlated with a LD stage, and is independently predictive of 
a favorable outcome.
Key Words: Small cell lung cancer, PD-L1, Immunohistochemistry, 
Prognostic factor.
(J Thorac Oncol. 2015;10: 426–430)
Lung cancer is the leading cause of cancer death worldwide.1 Small cell lung cancer (SCLC) is a histological subtype 
that accounts for approximately 15% of all lung cancer cases.2 
Systemic chemotherapy is the standard type of care for SCLC. 
Although SCLC shows a good response to initial treatment, 
most patients suffer disease recurrence and become refractory 
to chemotherapy. Despite intensive research, the prognosis of 
SCLC remains poor, and therefore new strategies to improve 
outcome are urgently needed.
Blockade of immune checkpoints with monoclonal anti-
bodies has also recently emerged as a new therapeutic tool in 
oncology.3,4 Programmed cell death 1 (PD-1), which belongs 
to the CD28 family of proteins, is a receptor expressed on the 
surface of T cells that regulates their activation and prolifera-
tion.3,4 Its ligand, programmed cell death-ligand 1 (PD-L1), 
is frequently overexpressed in many types of human cancer.5 
Recent clinical trials have indicated that inhibition of this 
pathway with anti-PD-1/PD-L1 antibodies exerts a promising 
antitumor effect against several human malignancies, includ-
ing non–small-cell lung cancer (NSCLC), melanoma, and 
renal cell cancer.6,7 Preliminary analysis of these trials sug-
gests that tumor expression of PD-L1 predicts response to 
PD-1/PD-L1-directed therapy. However, the clinical relevance 
of PD-L1 expression in SCLC has remained unclear. We 
therefore examined PD-L1 expression in SCLC and analyzed 
its associated clinicopathologic characteristics and prognostic 
relevance.
PATIENTS AND METHODS
Patients
We retrospectively screened 178 consecutive patients 
who were diagnosed as having SCLC at Kurume University 
Hospital between 2002 and 2013. Among these patients, 70 
were diagnosed only from cytological specimens, and six of 
the paraffin-embedded tissue blocks contained too few tumor 
cells to allow immunohistochemistry. To evaluate the expres-
sion, we excluded these samples. Adequate histological speci-
mens containing abundant tumor cells were available for 102 
of these patients, who were enrolled in this retrospective study. 
The tumor specimens were derived from primary lung lesions 
in 83 (81.4%) patients, liver metastases in four (3.9%), brain 
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metastases in three (2.9%), bone metastases in two (2.0%), 
skin metastases in three (2.9%), and lymph node metastases 
in seven (6.9%). The clinical characteristics of the patients, 
including age, sex, Eastern Cooperative Oncology Group 
performance status (PS), limited disease (LD)–extensive dis-
ease (ED) stage, serum lactate dehydrogenase (LDH) level, 
serum pro-gastrin-releasing peptide level, and serum neuron-
specific enolase (NSE) level, were recorded. LD stage was 
defined as location of disease within an anatomic region that 
could be safely encompassed within a tolerable radiation field, 
whereas ED stage was defined as extending beyond locore-
gional boundaries, possibly including malignant pleural or 
pericardial effusion, and hematogenous metastases. This 
study was conducted in accordance with the provisions of the 
Declaration of Helsinki and was approved by the Institutional 
Review Board of Kurume University Hospital.
Immunohistochemical Analysis 
of PD-L1 Proteins
We used 4-μm-thick sections of formalin-fixated, 
paraffin-embedded tissues. The sections were mounted on 
glass slides and then incubated with anti-rabbit monoclo-
nal antibody against PD-L1 (Abcam, Cambridge, United 
Kingdom) for immunohistochemical analysis with the use of 
BenchMark XT (Ventana Automated Systems, Inc., Tucson, 
AZ). Briefly, each slide was heat-treated using Ventana’s 
CC1 retrieval solution for 30 minutes, and incubated with 
the PD-L1 antibody for 30 minutes. This automated system 
used the ultraVIEW DAB detection kit with 3,3′ diamino-
benzidine as the chromogen (Ventana Automated Systems). 
All immunohistochemical analysis was evaluated by two 
experienced observers (A.K. and M.K.) who were unaware of 
the patients’ conditions. Spots for which the pathologists dis-
agreed regarding the staining category were reviewed jointly 
and a single consensus category was established. Cases with 
less than 5% tumor staining were considered negative as pre-
vious studies.8,9
Statistical Analyses
Correlations between PD-L1 expression and patient 
characteristics were analyzed using the χ2- or Fisher’s exact 
test for categorical variables. We evaluated whether param-
eters including PD-L1 expression were associated with the 
survival of SCLC patients. Overall survival (OS) was mea-
sured from administration of treatment or initial diagnosis 
until the date of death or last follow-up. Progression-free sur-
vival (PFS) was defined as the period from the date of initia-
tion of first-line treatment to the date of disease progression or 
death due to any cause. The Kaplan–Meier method was used 
to assess the patients’ survival curves and the log-rank test was 
used to evaluate the significance of differences between two 
groups. Multivariate regression was performed using the Cox 
proportional hazards model. All variables that had p values 
of less than 0.05 were included in the Cox model. All tests 
were two-sided, and differences were considered statistically 
significant at p less than 0.05. All of the statistical analyses 
were conducted using JMP version 10 (SAS Institute Inc., 
Cary, NC).
RESULTS
Patient Characteristics
The clinical characteristics of the 102 patients are shown 
in Table 1. The median age of the patients at diagnosis was 70 
years (range, 36–85 years). Eighty-nine (87.3%) of the patients 
were men, and 87 (85.3%) patients had a good PS (0–1). Forty-
one patients (40.2%) had LD and 61 (59.8%) had ED at the time 
of diagnosis. The median LDH level was 245 U/l (range, 138–
3476 IU/l). The LDH level was found to be lower than or equal 
to the upper normal limit of 229 IU/l in 37 patients (36.3%), 
and was higher than 229 IU/l in 65 patients (63.7%). The pro-
GRP and NSE serum levels were available in 101 (99.0%) and 
79 (77.5%) patients, respectively, and the median values were 
294 pg/ml (range, 12.6–33,300 pg/ml) and 22.4 ng/ml (range, 
5.2–581 ng/ml), respectively. ED-SCLC patients were treated 
with platinum-based chemotherapy as a first-line treatment. 
Among 41 LD-SCLC patients, 31 (75.6%) received concur-
rent chemoradiotherapy, three (7.3%) received platinum-based 
chemotherapy, and seven (17.1%) underwent surgical resection 
followed by platinum-based chemotherapy.
PD-L1 Protein Expression
Immunostaining for PD-L1 was observed in the 
membrane and/or cytoplasm of the tumor cells and stromal 
lymphocytes. Representative PD-L1 staining patterns in 
the tumor specimens are shown in Figure 1. Seventy-three 
(71.6%) SCLC patients had positive tumor PD-L1 staining.
TABLE 1.  Patient Characteristics and their Association with 
PD-L1 Expression
Variables
No. of 
Patients
PD-L1 Expression
p ValuePositive Negative
Age
  <70 51 39 12 0.272
  ≥70 51 34 17
Sex
  Men 89 66 23 0.186
  Woman 13 7 6
Performance status
  0–1 87 63 24 0.758
  2–3 15 10 5
Stage
  LD 41 35 6 0.011
  ED 61 38 23
Serum LDH level
  Normal 37 30 7 0.108
  Abnormal 65 43 22
Serum pro-GRP level
  Median 294 304 265 0.609
  Range 12.6–33,300 13.8–31,400 12.6–33,300
Serum NSE level
  Median 22.4 19.6 26.7 0.666
  Range 5.2–581 5.2–581 5.6–309
PD-L1, programmed cell death-ligand 1; LDH, lactate dehydrogenase; LD, 
limited disease; ED, extensive disease; Pro-GRP, pro-gastrin-releasing peptide; NSE, 
neuron-specific enolase.
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Correlation between PD-L1 Expression 
and Patient Characteristics
The relation between PD-L1 expression and patient 
demographics is shown in Table 1. Expression of PD-L1 
was significantly higher in SCLC patients with LD than in 
those with ED (p = 0.011). No significant correlation was 
observed between PD-L1 expression and age (p = 0.272), sex 
(p = 0.186), PS (p = 0.758), serum LDH level (p = 0.108), 
serum pro-gastrin-releasing peptide level (p = 0.609), and 
serum NSE level (p = 0.666).
Survival Analysis
At the time of analysis, the median duration of fol-
low-up was 11.4 months (range, 0.7–134.6 months). The 
PD-L1-positive group showed significantly longer OS than 
the PD-L1-negative group (median 16.3 months versus 7.3 
months, p < 0.001; Fig. 2). Univariate analysis revealed that 
a LD stage (p < 0.001), a good PS (p<0.001), a low serum 
NSE level (p<0.001), a normal serum LDH level (p = 0.039), 
and expression of PD-L1 (p < 0.001) were significantly asso-
ciated with a favorable OS, whereas none of the other fac-
tors examined was significantly associated with OS (Table 2). 
We performed multivariate analysis to examine which factors 
were associated with expression of PD-L1. Multivariate anal-
yses demonstrated that a good PS, a LD stage, and expres-
sion of PD-L1 were independent and significant predictive 
factors for OS (Table 3). Sub-analysis of ED-SCLC patients 
showed that the PD-L1-positive group had a longer OS than 
PD-L1-negative group (median 9.2 months versus 5.4 months, 
p = 0.037; Fig. 3A), whereas there was no significant differ-
ence in PFS between the positive and negative groups (median 
5.2 months in the positive group versus 4.6 months in the neg-
ative group, p = 0.747; Fig. 3B). In LD-SCLC patients, there 
was no significant difference in OS (median 25.5 months in 
the positive group versus 21.8 months in the negative group, 
 p = 0.146; Fig. 3C) and PFS (median 10.6 months in the posi-
tive group versus 7.9 months in the negative group, p = 0.083; 
Fig. 3D) between the positive and negative groups.
DISCUSSION
Although blockade of immune checkpoints with 
monoclonal antibodies has also recently emerged as a new 
therapeutic strategy in several malignancies,3,4 the clinico-
pathologic characteristics associated with PD-L1 expression 
in SCLC have remained largely unknown. Here, using immu-
nohistochemistry, we examined PD-L1 expression in 102 
specimens of SCLC, and found that expression of PD-L1 in 
SCLC (71.6%) was relatively higher than in NSCLC,10–12 and 
was correlated with the LD stage, and also corresponded to 
the subsets of patients who were more likely to have a good 
outcome.
Several studies have reported the association between 
clinicopathologic factors and PD-L1 expression in lung can-
cer.10–12 Some have shown that expression of PD-L1 is more 
correlated with a higher grade of differentiation, whereas oth-
ers have found no significant correlations.10,11 Additional stud-
ies will be needed to clarify why these factors are associated 
with PD-L1 expression.
We found that patients with expression of PD-L1 had 
significantly better survival than those with negative expres-
sion. Multivariate analysis revealed that expressions of PD-L1, 
a good PS, and a LD stage were significantly associated with 
better prognosis independently of the other factors examined. 
A B
FIGURE 1.  Positive PD-L1 immunohistochemical staining pattern (A) and negative immunohistochemical staining pattern (B). 
PD-L1, programmed cell death-ligand 1.
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FIGURE 2.  Kaplan–Meier overall survival curves for SCLC 
patients with positive and negative expression of PD-L1. 
SCLC, small-cell lung cancer; PD-L1, programmed cell 
death-ligand 1.
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Given that a LD stage has been reported as prognostic factor 
in SCLC patients, expression of PD-L1 might be related to 
a good prognosis. As far as we are aware, a significant asso-
ciation between PD-L1 expression and better prognosis has 
not previously been demonstrated for individuals with SCLC. 
These results are in line with previous studies showing that 
expression of PD-L1 is associated with better prognosis in 
patients with NSCLC, colorectal cancer, breast cancer, and 
malignant melanoma.10,12,14–17 In contrast to our study, sev-
eral previous studies have reported that expression of PD-L1 
protein was associated with poor prognosis in patients with 
NSCLC, esophageal carcinoma, gastric carcinoma, hepatocel-
lular carcinoma, pancreatic carcinoma, renal cell carcinoma, 
and ovarian carcinoma.11,18–26 These conflicting results may be 
due to a number of reasons. One explanation is that deter-
mination of PD-L1 expression in tumor samples has gener-
ally been performed by immunohistochemistry using various 
antibodies in different malignancies. Second, the threshold for 
positivity has not been clearly defined, and reproducibility has 
not been formally assessed. For future clinical applications, 
further efforts to standardize a quantitative assay for PD-L1 
expression are warranted.
TABLE 2.  Univariate Analysis of Prognostic Factors for 
Overall Survival
Factor Number
Median  
OS (mo)
HR  
(95% CI) p Value
Age
  <70 51 14.6 1.161 (0.755–1.778) 0.492
  ≥70 51 11.9
Sex
  Men 89 13.2 0.908 (0.512–1.761) 0.756
  Woman 13 17.6
Performance status
  0–1 87 15.2 0.227 (0.131–0.419) <0.001
  2–3 15 1.9
Stage
  Limited disease 41 25.5 0.254 (0.154–0.408) <0.001
  Extensive disease 61 8.4
Serum LDH level
  Normal 37 18.3 0.628 (0.398–0.974) 0.039
  Abnormal 65 9.7
Serum pro-GRP level
  Low (< median) 50 14.5 0.682 (0.440–1.054) 0.104
  High (> median) 51 12.9
Serum NSE level
  Low (< median) 39 18.0 0.433 (0.259-0.718) <0.001
  High (> median) 40 9.5
PD-L1 expression
  Positive 73 16.3 0.408 (0.257–0.664) <0.001
  Negative 29 7.3
OS, overall survival; HR, hazard ratio; CI, confidence interval; LDH, lactate 
dehydrogenase; Pro-GRP, pro-gastrin-releasing peptide; NSE, neuron-specific enolase; 
PD-L1, programmed cell death-ligand 1.
TABLE 3.  Multivariate Analysis of Factors for Overall Survival
Factor Hazard ratio 95% CI p Value
PS (0–1/2–3) 0.390 0.192–0.841 0.018
Stage (LD/ED) 0.403 0.199–0.804 0.010
NSE level (low/high) 0.671 0.358–1.225 0.196
LDH level (normal/abnormal) 1.130 0.628–1.995 0.679
PD-L1 expression (positive/negative) 0.435 0.241–0.803 0.008
CI, confidence interval; PS, performance status; LD, limited disease; ED, 
extensive disease; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; PD-L1, 
programmed cell death-ligand 1.
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FIGURE 3.  Kaplan–Meier curves for 
OS (A) and PFS (B) of ED-SCLC patients 
with high or low expression of PD-L1. 
Kaplan–Meier curves for OS (C) and PFS 
(D) of LD-SCLC patients with positive 
or negative expression of  
PD-L1. OS, overall survival; PFS, 
progression-free survival; ED, extensive 
disease; SCLC, small-cell lung cancer; 
PD-L1, programmed cell death-ligand 1; 
LD, limited disease.
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We further analyzed whether PD-L1 expression in 
tumor cells is correlated with PFS in LD- and ED-SCLC. 
We found no relevance between PD-L1 expression and PFS 
in SCLC, suggesting that PD-L1 expression may be a prog-
nostic factor rather than a factor predictive of the response 
to chemotherapy. Previous studies have shown that PD-L1 
expression is driven by various oncogenic signaling path-
ways.27–30 Accordingly, we speculate that effective chemo-
therapy may weaken anti-tumor immunity by regulating the 
expression of PD-L1. Additional studies will be needed to 
clarify these issues.
Our study had a number of limitations. One major weak-
ness was that the number of patients studied was relatively 
small. Second, the information was collected retrospectively; 
and third, PD-L1 expression was evaluated from formalin-fixed 
paraffin-embedded specimens obtained by trans-bronchial 
lung biopsy in most cases. Although most SCLC patients are 
diagnosed at a late disease stage, surgically resected samples 
containing an adequate number of tumor cells are not obtained 
in clinical practice.
In conclusion, we have demonstrated that expression 
of PD-L1 was present in over 70% of SCLC patients and 
was associated with a better prognosis. Further studies are 
warranted to clarify the role of PD-L1 expression, and the 
therapeutic effect of PD-1/PD-L1 blockade, in SCLC mod-
els and clinical trials. These data provide a basis for imple-
mentation of cancer immunotherapy in patients with SCLC.
REFERENCES
 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J 
Clin 2012;62:10–29.
 2. Ettinger DS. Overview and state of the art in the management of lung 
cancer. Oncology 2004;18:3–9.
 3. Pardoll DM. The blockade of immune checkpoints in cancer immuno-
therapy. Nat Rev Cancer 2012;12:252–264.
 4. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 pro-
motes T-cell apoptosis: A potential mechanism of immune evasion. Nat 
Med 2002;8:793–800.
 5. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN 
function increases B7-H1 expression and immunoresistance in glioma. 
Nat Med 2007;13:84–88.
 6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and 
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 
2012;366:2443–2454.
 7. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-
PD-L1 antibody in patients with advanced cancer. N Engl J Med 
2012;366:2455–2465.
 8. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent 
anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, 
clinical activity, pharmacodynamics, and immunologic correlates. J Clin 
Oncol 2010;28:3167–3175.
 9. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory 
response with B7-h1 expression in human melanocytic lesions supports 
an adaptive resistance mechanism of immune escape. Sci Transl Med 
2012;4:127–137.
 10. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell 
death-ligand 1 expression in surgically resected stage I pulmonary 
adenocarcinoma and its correlation with driver mutations and clinical 
outcomes. Eur J Cancer 2014;50:1361–1369.
 11. Chen YB, Mu CY, Huang JA. Clinical significance of programmed 
death-1 ligand-1 expression in patients with non-small cell lung cancer: 
A 5-year-follow-up study. Tumori 2012;98:751–755.
 12. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 
expression in non-small cell lung cancer. Lab Invest 2014;94:107–116.
 13. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of 
PD-L1 in lung cancer may contribute to poor prognosis and tumor cells 
immune escape through suppressing tumor infiltrating dendritic cells 
maturation. Med Oncol 2011;28:682–688.
 14. Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed 
cell death ligand 1 expression in colorectal cancer. Eur J Cancer 
2013;49:2233–2242.
 15. Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA 
expression is associated with increased TILs and better outcome in breast 
carcinomas. Clin Cancer Res 2014;20:2773–2782.
 16. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of pro-
grammed cell death-1 ligand 1 is a prognostic factor for malignant mela-
noma. Cancer 2010;116:1757–1766.
 17. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel 
cell carcinoma microenvironment: Association with inflammation, 
Merkel cell polyomavirus and overall survival. Cancer Immunol Res 
2013;1:54–63.
 18. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed 
death-1 ligand-1 and programmed death-1 ligand-2 expression in human 
esophageal cancer. Clin Cancer Res 2005;11:2947–2953.
 19. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical 
localization of programmed death-1 ligand-1 (PD-L1) in gastric carci-
noma and its clinical significance. Acta Histochem 2006;108:19–24.
 20. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly 
associates with tumor aggressiveness and postoperative recurrence in 
human hepatocellular carcinoma. Clin Cancer Res 2009;15:971–979.
 21. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic 
potential of the programmed death-1 ligand/programmed death-1 path-
way in human pancreatic cancer. Clin Cancer Res 2007;13:2151–2157.
 22. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in 
clear cell carcinoma of the kidney for prognostication and therapy. Clin 
Cancer Res 2007;13:709s–715s.
 23. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory molecule 
B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 
2005;104:2084–2091.
 24. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory 
B7-H1 in renal cell carcinoma patients: Indicator of tumor aggres-
siveness and potential therapeutic target. Proc Natl Acad Sci USA 
2004;101:17174–17179.
 25. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kid-
ney cancer. Clin Genitourin Cancer 2006;5:206–211.
 26. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 
1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of 
human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360–3365.
 27. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN 
function increases B7-H1 expression and immunoresistance in glioma. 
Nat Med 2007;13:84–88.
 28. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of 
MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 
expression that is reversible by MEK and PI3K inhibition. Clin Cancer 
Res 2013;19:598–609.
 29. Crane CA, Panner A, Murray JC, et al. PI(3) kinase is associated with a 
mechanism of immunoresistance in breast and prostate cancer. Oncogene 
2009;28:306–312.
 30. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 path-
way contributes to immune escape in EGFR-driven lung tumors. Cancer 
Discov 2013;3:1355–1363.
